Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Identifying tumor-specific antigens is crucial for developing effective immunotherapies.
• Major Histocompatibility Complex (MHC) class II pathway plays a key role in presenting antigens to CD4(+) T cells.

Purpose of the Study:

• To develop and apply a screening approach for identifying tumor antigens recognized by CD4(+) T cells.
• To discover novel tumor antigens for potential cancer treatment strategies.

Main Methods:

• A genetically engineered cell line expressing MHC class II pathway components was used.
• Screening of an invariant chain-complementary DNA fusion library was performed.
• Biochemical isolation methods were employed to identify antigens.

Main Results:

• A mutated form of human CDC27 was identified as an HLA-DR4-restricted melanoma antigen.
• A mutated form of triosephosphate isomerase was identified as an HLA-DR1-restricted antigen.
• The developed approach demonstrated general applicability for CD4(+) T cell antigen discovery.

Conclusions:

• The novel screening approach is effective for identifying tumor-specific antigens.
• Identified antigens, such as mutated CDC27 and triosephosphate isomerase, offer potential targets for cancer immunotherapy.
• This methodology could advance treatment strategies for cancer, autoimmune, and infectious diseases.